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Summary
Mucositis is still a leading side effect of high dose chemo-
therapy and irradiation delivered in autologous and allogeneic
bone marrow transplantation. In this double blind randomised
study, we tested the efficacy of sucralfate for the prevention of
mucositis induced by such conditioning treatments. Treatment
was started one day before conditioning regimen and patients
were prospectively evaluated. The main endpoint was severe
mucositis that was more frequent in the placebo group than in
the sucralfate group (47% vs. 29%, P = 0.07). This trend was
confirmed after adjustment on total body irradiation (TBI)
(P - 0.06), the sole stratification parameter. Interestingly,
patients receiving sucralfate showed a significant reduction of
diarrhoea (25% vs. 53%, P = 0.005). Overall, the preventive
administration of sucralfate appears to be an effective proce-
dure to diminish the occurrence of severe oral and intestinal
mucositis in patients treated by high dose chemotherapy alone
or combined with TBI before bone marrow transplantation.
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Introduction
Mucositis is a dose-limiting toxicity that frequently
complicates the course of autologous or allogeneic bone
marrow transplantations (BMT) [1]. Efforts should focus
on its prevention, since treatment of established lesions
remains unsuccessful. Efficient prevention of toxic dam-
age induced by conditioning regimens on intestinal mu-
cosa will not only protect the patient from major pain,
abdominal discomfort and diarrhoea, but could also
improve food intake and reduce the risk of infections by
diminishing the risk of microbial translocation from the
digestive tract into the bloodstream [2].
Sucralfate is a complex salt of sucrose sulfate and
aluminium hydroxide which is commonly used for the
treatment of acute duodenal and gastric ulcer diseases.
Its main mechanism of action is thought to be the
adhesion of the drug to ulcerated mucosa, forming a
physical barrier to protect them from acid, bile salts and
pepsin. In addition, sucralfate has multiple biological
effects, such as the induction of prostaglandin and
mucus production, an increase in mucosal blood flow
and the binding of epithelial growth factor and basic
fibroblastic growth factor to tissues [3]. This suggested
to us that this drug can be active in the prevention of
mucositis. We report the results of a monocentric pro-
spective randomised double blind study designed to
evaluate the efficacy of sucralfate to prevent mucositis
after BMT.
Patients and methods
Treatment
Patients fulfilling the enrolment criteria (patients > 15 years old. hospi-
talised for a allogeneic or autologous BMT. provision of a written
informed consent) were randomly allocated to the sucralfate or the
placebo group, a few days before the beginning of the conditioning
regimen. Conditioning regimens were categorised in four groups,
based on their probability to induce mucositis (very high risk, high
risk, intermediate risk, low risk) (Table 1). Randomisation was strati-
fied on Total Body Irradiation (TBI). Patients were instructed to ingest
one dose package (2 g) of sucralfate or an identical-appearing placebo
every three hours daily and once during the night in case of wakening,
for a maximum of seven mouthwashes per 24 hours. Sucralfate or
placebo were to be kept within the mouth for one minute before being
swallowed. Patients were asked to avoid drinking and eating during the
first hour after treatment ingestion. Treatment was initiated after initial
oral evaluation, one day before conditioning regimen and continued
until bone marrow recovery (ANC > 0.5 x 106/l) or until the end of
mucositis (in the case of persistent mucositis after bone marrow
recovery).
Patient evaluation
Patients were examined twice weekly from the first day of conditioning
regimen until bone marrow recovery or resolution of clinical signs of
mucositis. The clinical examination was performed by two physicians
only, and results were prospectively recorded. The oral status was
scored according to a toxicity grading adapted from OMS criteria for
grafted patients (Table 2). The primary objective was to compare the
occurrence of severe stomatitis (grade 3-4). Secondary objectives were
to define (i) the duration of mucositis, (ii) the rate and severity of
diarrhoea, and (iii) the caloric intake achieved by oral nutrition.
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Table I. Patients' characteristics before inclusion in study.
Sex
Male
Female
Diagnosis
AL
CML
NHL
HD
Germinal tumour
Other
Previous chemotherapy
1 line
2 lines
3 lines
4 lines
Previous radiotherapy
Previous mucositis
Conditioning regimen
Group 1
Group 2
Group 3
Group 4
Total body irradiation
Single dose (10 Gy)
Hyperfractionated (14 Gy)
Other
Sucralfate
// = 51 (%)
34
33
11 (22)
4(8)
15(29)
9(18)
4(8)
8(16)
50 (98)
18
20
II
1
14 (27)
28 (57)
5
25
6
15
30 (59)
18(60)
10(33)
2(7)
Placebo
n = 51 (%)
34
33
18 (35)
5(10)
10(20)
4(8)
6(12)
8(16)
50 (98)
18
23
5
4
12 (24)
35 (69)
6
24
10
11
30 (59)
16(53)
10 (33)
4(13)
P-value
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Abbreviations: AL - acute leukaemia: CML - chronic myelogenous
leukaemia; NHL: non-Hodgkin lymphoma; HD - Hodgkin's disease,
BMT - bone marrow transplantation; PBSC - peripheral blood stem
cells; NS - not significant.
Groups of conditioning regimens: Group I very high risk. TEC:
TBI (single dose TBI at 10 Gy or hyperfractioned TB1 at 14 Gy) +
cyclophosphamide (120 mg/kg) + etoposide (60 mg/kg); Group 2
high risk TBI + cyclophosphamide (120 mg/kg), TBI + melpha-
lan (140 mg/m2). TAM 12: TBI + cytarabine (12 g/m2) + melpha-
lan (120 mg/m2). TL1 (total lymphoid irradiation) + cyclophospha-
mide (120 mg/kg). Group 3 intermediate risk: BuCy: busulphan (16
mg/kg) + cyclophosphamide (120 mg/kg), PEC: cisplatine (200 mg/
m2) + cyclophosphamide (120 mg/kg) + etoposide (1800 mg/m2),
CARBOPEC: carboplatine (800, 1200, or 1600 mg/m2) + cyclophos-
phamide (120 mg/kg) + etoposide (1800 mg/m2). BusPAM: busul-
phan (16 mg/kg) + melphalan (140 mg/m2), PAM: melphalan
only (140 mg/m2); Group 4 low risk. BEAM: BCNU (300 mg/m2) +
etoposide (400 mg/m2) + cytarabine (400 mg/m2) + melphalan (140
mg/m2) BEAC: BCNU (300 mg/m2) + etoposide (400 mg/m2) +
cytarabine (400 mg/m2) + cyclophosphamide (120 mg/kg).
Table 2 Adapted toxicity grading for evaluation of oral mucosa.
Grade 0 No mucositis
Grade 1 Erythema or whitish mucosa
Grade 2 Superficial erosive lesions (< 20% of mucosa)
Grade 3 Extensive erosive lesions or ulcerations or painful
swallowing
Grade 4 Impossibility to swallow and/or to protrude the
tongue
Grade 0, I, 2 were grouped as 'mild' and grade 3. 4 as 'severe'
Statistical methods
It was estimated that 100 patients should be included to demonstrate a
minimal difference of 35% in the rate of severe mucositis (two tailed
test, a = 5%, (? = 5%). Analyses were carried out on the intention-to-
treat principle. Differences between groups were evaluated by x2 test or
Fisher's exact test for categorical variables and Student's /-test for
continuous variables (two-sided tests). Cumulative mucositis rates
were estimated by the Kaplan-Meier method and the corresponding
curves were compared by the log-rank test. This study was approved by
local and institutional ethical committees.
Results
Patients entered this trial from April 1991 to November
1993. A total of 105 patients were randomised, 53 in the
sucralfate arm and 52 in the placebo arm. Three patients
could not be included in the analysis because of recur-
rence of haematological disease after randomisation
(two in sucralfate and one in placebo group). The analy-
sis was thus performed on 51 patients in each group.
Baseline characteristics in the two groups were similar
(Table 1), in particular the number of previous therapies
and the type of conditioning regimens. Although the
incidence of mucositis of any grade was similar in both
arms (84% in the sucralfate arm versus 88% in the
placebo arm), the proportion of patients with grade 3-4
oral mucositis was higher in the placebo group than in
the sucralfate group (47% vs. 29%, P = 0.07). An elevated
proportion of grade 3/4 mucositis was also observed in
allografted patients (82% vs. 17% for autografted pa-
tients, P< 0.0001), and in patients treated by TBI (50%
vs. 21%, P<0.01). After adjustment on TBI (the sole
stratification parameter), the P-value comparing the
frequence of grade 3-4 mucositis in the sucralfate and
the placebo arms was 0.06. Acute GvHD was diag-
nosed in 57% of patients (8 of 14) in the sucralfate arm
and 47% (8 of 17) in the placebo arm, with upper
digestive tract involvement in three cases (two cases in
the sucralfate group and one case in the placebo group).
The incidence of oral mucositis was not significantly
influenced by acute GVHD and the growth factors
administration.
Interestingly, we observed a highly significant decrease
of the occurrence of diarrhoea in the sucralfate group
(25% vs. 53%, P = 0.005). Finally, sucralfate treatment
can favour the recovery of enteral alimentation, with, at
the fourth week post-graft, a mean caloric intake of 647
Kcal in the sucralfate group compared with 409 in the
placebo group (P - 0.04). No difference was noted
concerning the duration of oral mucositis, the incidence
of vomiting, gastrointestinal haemorrhage, or septicae-
mia, as well as the use of antibiotics, antivirals, and
analgesic drugs (data not shown). The actuarial survival,
evaluated from the first day of randomisation until bone
marrow recovery, was similar in both groups.
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Conclusion
In this prospective monocentric randomised study, the
preventive administration of sucralfate appeared to effi-
ciently diminish the discomfort induced by conditioning
regimen of BMT, with less patients suffering from diar-
rhoea. A trend was also observed (P = 0.06) for a
diminution of severe stomatitis. The difference between
placebo and sucralfate groups concerning this endpoint
was not as important as anticipated, because the rate of
severe mucositis was lower than expected in the placebo
group. This was probably due to the protective effects
mediated by mechanical mouth washes with placebo
solution that allow the repeated removal of drugs elim-
inated in the saliva. The impressive reduction of diarrhoea
could appear as more surprising, but can be explained
by the well established intestinal cytoprotector proper-
ties of swallowed sucralfate [4]. The overall results ob-
tained in this preventive study confirm and extend what
was observed in a previous randomised study testing
sucralfate for the prevention of chemotherapy-induced
mucositis, in which a significant reduction in oedema,
erythema and ulceration was reported in a low number
of evaluable patients receiving a combination of 5-fluo-
rouracil and cisplatin [5]. In contrast, the results of a
recent randomised double-blind study indicated that
sucralfate was not effective to treat 5-fluorouracil sto-
matitis, without any difference between the investiga-
tional and the placebo arms [6]. However, in this last
trial, sucralfate was not administered as a prophylactic
procedure, but only in patients developing mucositis
despite an effective preventive cryotherapy with ice chips
[7]. Furthermore, stomatitis was evaluated by historical
means and not in a prospective manner as in the present
work.
In conclusion, although sucralfate is probably poorly
active to treat established mucosal damage induced by
cytotoxic drugs, it appears to be an effective drug for the
prevention of severe oral and intestinal mucositis in
patients treated by high dose chemotherapy (and TBI)
before BMT. The long-term (several weeks) administra-
tion of sucralfate is difficult in this setting, due to the
important nausea occurring after BMT. Further clinical
research should determine whether a short-term (one or
two weeks) prophylactic administration can also protect
the patient from this severe side effect.
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